← Back to patent-cliff list
BRM-424
Tier C — Watch / tradeBRM-424
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：神经营养性角膜炎, Keratitis
Regional status
US
Phase II
2024-07-31
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BRM-424?
Approved indications include: 神经营养性角膜炎, Keratitis.
When does the BRM-424 patent expire?
No public expiry year is available for BRM-424 yet; this page updates once verified.
How do I get a quote for BRM-424 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03